The University of Michigan Comprehensive Cancer Center (UMCCC) requests the sixth renewal of its core grant since the initial NCI award in 1988. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director, supported by a strong, nationally recognized senior leadership team. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of well-funded basic, clinical and prevention programs in cancer research and the development of shared core resources. The Cancer Center's 13 research programs include six basic research programs in Cancer Genetics, Cancer Cell Biology, Radiation Sciences, Molecular Imaging, Experimental Therapeutics and Tumor Immunology Host Response; five clinical research programs: Hematologic Malignancies/BMT, Breast, Prostate, Gl and Head and Neck cancers; and two prevention programs Biomedical and Sociobehavioral. Support is requested for a total of 18 shared core facilities, including 13 existing cores. Clinical Trials, Biostatistis, Tissue and Molecular Pathology, Tumor Imaging, Morphology, Flow Cytometry, Experimental Irradiation, Transgenic Mouse, Vector, Immune Monitoring, Genomics, Informatics, Health Communications and five new cores: Patient and Population Sciences, High Throughput Screening, Pharmacokinetics, Structural Biology and Xenograft. Funds are also requested for development, senior leadership, planning and evaluation and administration to support center goals. The UMCCC's 337 members have contributed many high impact discoveries over this grant period. The Cancer Center's mission of the conquest of cancer through innovation and collaboration is further evidenced by the high degree of intra- (15.6%) and inter- (35.4%) programmatic publications published in this grant period. The UMCCC's success is underscored by its current ranking as #1 in NCI funding among all matrix cancer centers. The Medical Center has continued to make substantial commitments to the Cancer Center in space, financial support and designation of cancers as among its highest priorities for both clinical and research investment. The acquisition of the former Pfizer campus, now called North Campus Research Complex, represents an unparalleled opportunity for cancer discovery over the next grant period.

Public Health Relevance

The goals of the U of M Comprehensive Cancer Center are to foster research productivity, promote interaction and collaboration and optimize the institution's strengths and unique scientific opportunities to advance cancer prevention, diagnosis, treatment and survivorship.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-27
Application #
8896442
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-06-01
Project End
2017-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
27
Fiscal Year
2015
Total Cost
$6,097,616
Indirect Cost
$2,173,830
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757
Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224
Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224
Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458
Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865

Showing the most recent 10 out of 1493 publications